Lataa...
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
BACKGROUND: A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). A number of add-on therapies, including monoclonal antibodies (namely omalizumab) and more recently tiotropium bromide have been recommende...
Tallennettuna:
| Julkaisussa: | Cost Eff Resour Alloc |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5789632/ https://ncbi.nlm.nih.gov/pubmed/29422778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-018-0089-8 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|